STING1 and ovarian carcinoma: Treatment with different ATRi results in innate immune and T cell activation mediated by cGAS-STING pathway in various mouse models of cancer, including those for prostate cancer [60], hepatocellular carcinoma [34] and ovarian cancer [61].